STDAF News Alert Stada Arzneimi Namen (STDAF) 31.3000 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stada Arzneimi Namen (STDAF) 31.3000 $STDAF

Stada: Russia-Discount Gives This Drug Maker 17% Immediate Upside
Dieter Plas - at Seeking Alpha - Thu Dec 04, 2:53PM CST


Stada Arzneimittel's (STDAF) CEO Hartmut Retzlaff on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 1:56PM CST


Europe Biosimilars Market & Pipeline Insight 2014
M2 - Tue Oct 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bblsk8/europe) has announced the addition of the "Europe Biosimilars Market & Pipeline Insight" report to their offering. Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic incentives along with favorable pricing and reimbursement policies adopted across multiple markets in Europe. The current biosimilars market is highly fragmented in nature due to their accessibility in various therapeutic categories. The European biosimilars market is divided into various categories: Granulocyte-colony stimulating factor (G-CSF or GCSF), erythropoiesis-stimulating agents (ESAs) and somatropin biosimilars, Insulin, mAbs and follitropin. The present market fragmentation is driven by the availability of particular biosimilar products which were introduced over a decade ago. These products created niche among them and resulted in inclination toward a particular segments over a period of time. One of the most promising factors responsible for the development of biosimilars market is the patent expiration of reference drugs. The European biosimilars market is experiencing tremendous growth as blockbuster biologic drugs are going off-patent. The entry of new biosimilars due to patent expiry into various therapeutic indications has created a new category for the biosimilars. For instance, Ely Lily and Boehringer Ingelheim have already got marketing authorization of their biosimilar insulin in June'2014 even as the current diabetes drug (Lantus) marketed by Sanofi will go off patent in February'2015. The competitive pricing and reimbursement policies adopted by country specific regulators are also promoting the introduction of biosimilars in European market. The newly introduced biosimilars are approximately 20-30% cheaper and hence results in high level of acceptability among patients and physicians in comparison to originator molecule. The benefits of using the biosimilars include reimbursement provided by many governments which further decreases the financial burden from the patients as result of which they do not revert to originator molecules. Europe Biosimilars Market & Pipeline Insight Report Highlights: - Biosimilars Market Overview & Trend Analysis by Country - Biosimilars Introduction Timeline in Europe - Biosimilars Development & Market Authorization Guidelines - Biosimilars Clinical Pipeline by Phase, Indication, Company & Country - Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country - Europe Biosimilars Pipeline: 93 Biosimilars - Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine) Key Topics Covered: 1. Europe Biosimilars Market Overview 2. Europe Biosimilars Market Trend Analysis by Country 3. Biosimilars Introduction Timeline in Europe 4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario 5. Europe Biosimilars Market Dynamics 6. Future Prospectus of Biosimilars in Europe 7. Regulatory & Approval Authorities: EMA & CHMP 8. Biosimilars Development & Market Authorization Guidelines 9. Europe Biosimilars Clinical Pipeline by Phase, Indication, Company & Country 10. Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country 11. No Development Reported in Biosimilars Clinical Pipeline 12. Competitive Landscape - Apotex - Celltrion Healthcare - Finox Biotech - Hexal - Hospira - Medice Arzneimittel P?tter - Sandoz - Stada Arzneimittel - Teva Pharma For more information visit http://www.researchandmarkets.com/research/bblsk8/europe

Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
M2 - Thu Jul 31, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l95k93/global) has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering. Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson's disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson's disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson's disease patients under certain circumstances. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by MOA 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Late-Stage Pipeline Candidates 18. Other Prominent Vendors 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Novartis AG - Teva Pharmaceutical Industries Ltd. - Abbvie Inc. - Akorn Inc. - Astellas Pharma Inc. - Desitin Arzneimittel GmbH - Endo International plc - F. Hoffmann-La Roche Ltd. - H. Lundbeck A/S - Kyowa Hakko Kirin - Merck & Co. Inc. - Orion Corp. - STADA Arzneimittel AG - UCB Inc. - US WorldMeds LLC - Valeant Pharmaceuticals International Inc. For more information visit http://www.researchandmarkets.com/research/l95k93/global
AKRX: 36.47 (+0.43), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), GSK: 42.85 (+0.11), VRX.TO: 162.98 (-0.62), NVS: 93.91 (+0.66)

World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ACT: 254.20 (-1.68), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), MNTA: 11.42 (-0.06)

Global Biosimilar Market Outlook 2018 Report Discusses Major Trends and Drivers in Detail
M2 - Wed Feb 26, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/z8qpnt/global_biosimilar) has announced the addition of the "Global Biosimilar Market Outlook 2018" report to their offering. The global biosimilars market is at a crucial turning point, as biosimilars are gaining wide acceptance around the world, with regulatory pathways being clearly defined in every region and R&D investments being at an all time high. Several biosimilars have entered the market over the past 2-3 years. In 2008, Merck, one of the big pharma manufacturers, embraced biosimilars. Large scale partnerships to develop biosimilars are also being announced such as those between Samsung and Biogen, Amgen and Watson, Dr. Reddy's and Merck Serano. According to our latest research report, Global Biosimilar Market Outlook 2018, although the current biosimilars market is small, the future looks optimistic with number of innovative biologics going off patent. The report discusses major trends and drivers in detail and the influence they will have on the market. Emerging markets will play the role of a major driver for the biosimilars market, which will be attributed to the local policies and the biosimilar attitude of the regions. The governments in the emerging economies are encouraging the growth of biosimilars by defining clear regulatory pathways. In the report, the author has segmented the biosimilars market into various categories such as EPO (Erythropoietin), HGH (Human Growth Hormone), IFN (Interferon), mAb (Monoclonal Antibody), Insulin and G-CSF (Granulocyte Colony Stimulating Factor). Each market has been analyzed in terms of major approved biosimilars, drug pipeline, and the impact of patent expirations of important biologics. Similarly, major geographies are also discussed. Apart from the most regulated market of Europe, other economies such as US, India, China and Korea have been discussed. The regulatory scenario of all the economies has been presented. India, for example, recently announced its much awaited new and simple regulatory guidelines, Guidelines on Similar Biologics. Companies Mentioned: - 3 SBio Inc. - Biocon Limited - Bioton - Celltrion Pharm Inc. - Dong-A Pharmaceutical Co., Ltd - Dr.Reddy's Labs (DRL) - Hexal AG - Hospira - Intas Pharmaceuticals Ltd. - LG Life Sciences - Ratiopharm GmbH - Reliance Life Sciences - Sandoz GmbH - Shantha Biotechnics Limited - Stada Arzneimittel - Teva - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/z8...biosimilar About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15)

Viphya Private Secondary School Female Students March to Mzuzu Police Over Sexual Harassment
by Salome Gangire - All Africa Global Media - Sat Feb 15, 4:37AM CST
Viphya Private Secondary School female students Monday morning marched to Mzuzu Police Station to complain about sexual harassment they allegedly face from one of their male teachers.
BIIB: 340.89 (+5.13), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), AGN: 210.12 (+0.95), NVO: 43.80 (+1.08), GILD: 91.29 (+1.84), BAX: 74.45 (-0.04), MRK: 57.46 (+0.25), CELGZ: 3.34 (-0.01), NVS: 93.91 (+0.66)

Biosimilars Market Report, 2018: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins & Recombinant Peptides
M2 - Thu Jan 30, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/lz28ls/biosimilars) has announced the addition of the "Biosimilars Market Report, 2018: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins & Recombinant Peptides" report to their offering. The global market is segmented on the basis of products, applications, and services. By product, the global biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further classified into insulin, granulocyte colony-stimulating factor (G-CSF), interferon, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Glucagon and calcitonin are considered under the recombinant peptides segment. The recombinant glycosylated proteins segment is the largest segment of the market with a share of 40% of the global market in 2013. Of all the products, monoclonal antibodies will be the fastest-growing segment at an estimated CAGR of 41.9% from 2013 to 2018. Following this, insulin will be the second-fastest growing market from 2013 to 2018.The growth is attributed to the rise in incidences of diabetes; the ongoing patent expiration of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of biosimilars of insulin. By application, the market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and others (female infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, and chronic kidney failure). Oncology is the largest and fastest-growing segment of the global biosimilars market. This is attributed to the increasing prevalence of oncology along with the rise in aging population and the changing lifestyles. The global market will be worth $2.0 billion by 2018, growing at a CAGR of 20.1% during the forecast period (2013 to 2018). The major factors driving the growth of the market are the launch of new biosimilars (monoclonal antibodies, filgrastim, and follitropin); ongoing clinical research on potential pipeline products; patent expirations of various biologics such as Neupogen, Humira, and Lantus; and the increasing demand for first-wave biosimilar products such as somatropin, filgrastim, and erythropoietin. Scope of the Report Product - Recombinant Non-glycosylated Proteins -- Insulin -- Human Growth Hormone -- Granulocyte Colony--stimulating Factor (G--CSF) -- Interferons - Recombinant Glycosylated Proteins -- Erythropoietin -- Monoclonal Antibodies -- Follitropin - Recombinant Peptides -- Glucagon -- Calcitonin Service - Contract Manufacturing Organizations (CMO) - Contract Research Organizations(CRO) - Others (Bioinformatics and Sales & Marketing Services) Application - Oncology - Blood Disorders - Chronic & Autoimmune Diseases - Growth Hormone Deficiency - Infectious Diseases - Others Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Industry Analysis 6 Global Biosimilars Market, By Product 7 Global Biosimilars Market, By Application 8 Global Biosimilars Service Market 9 Geographic Analysis 10 Competitive Landscape 11 Company Profiles - Actavis, Inc - Amgen, Inc - Biocon Ltd - Celltrion, Inc - Cipla Ltd - Dr Reddy's Laboratories Ltd - Emcure Pharmaceuticals Ltd - Hospira, Inc - Lg Life Sciences Ltd - Merck Kgaa - Mylan, Inc - Ranbaxy Laboratories Ltd - Roche Holding Ltd - Sandoz International GMBH (Division Of Novartis International Ag) - Stada Arzneimittel Ag - Synthon - Teva Pharmaceutical Industries Ltd - Wockhardt Ltd For more information visit http://www.researchandmarkets.com/research/lz...iosimilars
ACT: 254.20 (-1.68), AMGN: 160.67 (+3.15), TEVA: 57.09 (+0.33), NVS: 93.91 (+0.66)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 100

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 76

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 89

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 87

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 50

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the Luxury of the Mercedes-Benz EQS: Test Drive Today

Updated Category News Views 200

Experience the Mercedes-Benz EQS Test Drive at Arrowhead Drivers have a wonderful opportunity to immerse themselves in the world of electric luxury with the EQS at Mercedes-Benz of Arrowhead. This dealership is dedicated to providing an exceptional test drive experience, allowing potential buyers to see why this vehicle stands out in its class. With the surge in interest...

Continue Reading
Upcoming Financial Results and Conference Call for PROREIT

Updated Category News Views 103

Important Announcement from PROREIT PRO Real Estate Investment Trust, commonly known as PROREIT, is gearing up to share its financial performance for the 2024 fiscal year as well as the results for the fourth quarter. Scheduled for post-market release, this wave of data promises valuable insights for investors and stakeholders alike. The release will take place on an...

Continue Reading
Hearthside Food Solutions Seeks Bankruptcy Protection Amid Debt Issues

Updated Category News Views 293

Hearthside Food Solutions Files for Bankruptcy Hearthside Food Solutions has taken a significant step by filing for bankruptcy protection amidst deep financial strains. This decision comes as the company aims to reduce its staggering $1.9 billion debt and undertake a much-needed restructuring of its operations. The move follows troubling investigations into allegations of...

Continue Reading
New Affordable Housing Community Launched in San Antonio

Updated Category News Views 149

New Affordable Housing Community Opens in San Antonio The NRP Group, a leading developer known for its quality multifamily housing, has partnered with the City of San Antonio to celebrate the opening of a new affordable housing community called Los Arcos at Vida. This significant development, featuring 324 rental units, represents a crucial step forward in the ongoing...

Continue Reading
Insights on Dollar Tree's Stock Activity and Market Trends

Updated Category News Views 131

Understanding Dollar Tree's Investment Climate In the recent environment of stock trading, Dollar Tree (NASDAQ: DLTR) has caught the attention of many investors. A noticeable trend has emerged among deep-pocketed investors adopting a bearish stance towards the company. This change in sentiment is worth noting for those keeping tabs on the market. Market Activity Insights...

Continue Reading